Bora Pharmaceuticals to acquire Baltimore-Camden manufacturing site from Emergent BioSolutions, for $30m.

Bora Pharmaceuticals, a contract development and manufacturing organization, agreed to acquire Baltimore-Camden manufacturing site from Emergent BioSolutions, a provider of public health products to government and healthcare providers, for $30m. “This transaction not only demonstrates our commitment to our growth strategy and plans for expansion in North America, but also enables us to expand our offering for our biologics customers. We look forward to working with the hugely talented team at the facility and supporting new and existing customers as we grow and develop the facility,” Bobby Sheng, Bora Group Chairman and CEO.